Skip to main content
Article thumbnail
Location of Repository

Rapid progression of prostate cancer in men with a BRCA2 mutation

By S A Narod, S Neuhausen, G Vichodez, S Armel, H T Lynch, P Ghadirian, S Cummings, O Olopade, D Stoppa-Lyonnet, F Couch, T Wagner, E Warner, W D Foulkes, H Saal, J Weitzel, A Tulman, A Poll, R Nam and P Sun

Abstract

Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients. In this study, we compared survival of men with a BRCA2 mutation and prostate cancer with that of men with a BRCA1 mutation and prostate cancer. We obtained the age at diagnosis, age at death or current age from 182 men with prostate cancer from families with a BRCA2 mutation and from 119 men with prostate cancer from families with a BRCA1 mutation. The median survival from diagnosis was 4.0 years for men with a BRCA2 mutation vs 8.0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation

Topics: Genetics and Genomics
Publisher: Nature Publishing Group
OAI identifier: oai:pubmedcentral.nih.gov:2480973
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2007). Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.